Tilray Brands, Inc. (TLRY)

Tilray stock price forecast as it faces major headwinds

Tilray stock price has surged in the past few weeks, with most of the gains happening on Monday when it surged by over 60%, which brought its market capitalization to over $2 billion. It has now soared by over 440% from its lowest level this year.

Best Canadian Cannabis Stocks to Watch for Growth and Opportunity

The U.S. cannabis industry has expanded rapidly, now generating over $33 billion in annual sales. Analysts project the market could exceed $56 billion by 2030. These figures highlight the growing opportunities for Canadian cannabis companies to target U.S. partnerships and eventual federal legalization. Recently, U.S. lawmakers renewed discussions about rescheduling cannabis under federal law. This sparked optimism and short-term volatility across cannabis stocks. Canadian firms remain positioned to benefit from regulatory progress and expanding cross-border demand. Their strategies include scaling production, diversifying product lines, and investing in branded distribution. As the industry evolves rapidly, investors must closely monitor these developments.

Wall Street Breakfast Podcast: Weed Stocks Light Up

Cannabis stocks surged after Trump endorsed CBD for senior healthcare, citing its potential to revolutionize treatment and reduce healthcare costs. Shares of TLRY, CGC, CRON, and ACB soared double digits, with related ETFs MSOS and MJ also posting significant gains.

Tilray, a Global Leader in Medical Cannabis, Announces Expansion of Premium Craft Cannabis Production at its Advanced EU-GMP Facility in Germany; Tilray Medical Enhances Tilray Craft Cannabis Portfolio with New Patient-Centered Offerings

NEUMÜNSTER, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Medical a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare today announced the expansion of its Tilray Craft portfolio in Germany with five new cannabis flower products produced in Germany at Tilray's EU‑GMP certified facility in Neumünster as part of the BfArM in‑country cultivation program. The additions reflect Tilray's ongoing commitment to providing physicians and pharmacies with a diverse range of quality, EU‑GMP certified medical …

Markets Keep at All-Time Highs - Lots of Data Expected This Week

Pending Homes Sales were better than expected, and cannabis stocks got a boost. But there is a lot of grist for the mill coming out in the coming days.

Cannabis stocks surge after Trump posts video touting Medicare coverage for CBD

Tilray Brands surged nearly 20% and was up 36% after market open, while Canopy Growth jumped about 20% and Cronos Group rose 13%.

Tilray Brands: What's Next For TLRY Stock?

Tilray Brands (NASDAQ: TLRY) has witnessed a considerable surge, rising nearly 200% from $0.42 in early July to its present price of $1.24. This increase is largely attributed to the Trump administration's deliberation on reclassifying cannabis from a Schedule I to a Schedule III substance.

Tilray stock price sits and waits for Trump cannabis rescheduling

The Tilray Brands stock price has staged a strong bullish rebound in the past few months, moving from a low of $0.352 in June to $1.25, up by 256%. Here's what to expect as market participants wait for the cannabis rescheduling.

Broken Coast Cannabis Brand Launches Premium and Limited BC Selects Line and Unveils New Strain “Sprits 26”, Elevates Craft Portfolio with Modern Blue Dream Release

NANAIMO, British Columbia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle and consumer-packaged goods company, announced that its premium craft cannabis brand Broken Coast is launching BC Selects, a new limited-edition line of premium cannabis flower that features unique phenotypes from its proprietary genetic library. The first strain in this series, Sprits 26, is now available exclusively in British Columbia, underscoring Broken Coast's dedication to precision and excellence in craft cannabis production.

3 Top Canadian Marijuana Stock Choices For A Possible Breakout In 2025

The cannabis industry continues to demonstrate why it deserves the same opportunities as other legitimate businesses. From an investment side, there are many who have put up big money in various global regions to be a part of this booming industry. Places like Canada and the USA are where the main markets exist. Now there are several parts to this, both bitter and sweet. Here is why it could be a bit bitter is with the potential of cannabis being rescheduled, it will give a major leg up to corporate cannabis versus small batch mom and pop cultivators.

Pot Stocks Plunge After Rally: Is Betting on Rescheduling Worth the Risk?

Key Points in This Article: Cannabis stocks surged in 2018-2019 on federal legalization hopes but crashed as progress stalled.

Tilray Brands shares gain as analysts boost price target on cannabis rescheduling optimism

Tilray Brands (NASDAQ:TLRY) shares continued to gain momentum on Tuesday after the cannabis firm saw its price target boosted by Jefferies analysts. The analysts, who maintained a ‘Buy' rating on Tilray, upped their price target to $2 from $1.50, citing growing optimism about a potential shift in US federal cannabis policy.

Top Canadian Marijuana Stocks to Watch in 2025 : Industry Growth and Legalization Updates

Investors are closely watching Canadian cannabis stocks this week amid rising U.S. industry momentum. The U.S. cannabis market hit an estimated $38.5 billion in 2024 and may grow at a compound annual growth rate (CAGR) of about 11–12 percent through the late 2020s. Meanwhile, several states are advancing reform. Notably, Delaware began adult-use cannabis sales on August 1, 2025. Moreover, at the federal level, the Trump administration signaled plans to reschedule marijuana from Schedule I to Schedule III, possibly within weeks. This could ease restrictions and boost stock sentiment. Altogether, these developments underline strong thematic tailwinds. Thus, Canadian cannabis stocks …

Tilray Brands: Path To 5x Growth For TLRY Stock

Tilray Brands (NASDAQ: TLRY) stock has already climbed 2x in the past month after reports that the Trump administration may reclassify marijuana, underscoring the market's recognition of this transformative catalyst. But how significant could this opportunity become for Tilray?

Tilray's High Hopes: The Catalyst Driving Cannabis Stocks

A fairly consistent climb in Tilray Brands' NASDAQ: TLRY stock price has started to capture the market's attention. After touching a 52-week low of 35 cents, the stock has rallied dramatically, climbing over 133% in the last three months on massive trading volume.

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $1.03, denoting a -12.71% move from the preceding trading day.

Tilray Brands: Improving Fundamentals, De-Risked Balance Sheet, And A Re-Igniting Narrative

Tilray Brands: Improving Fundamentals, De-Risked Balance Sheet, And A Re-Igniting Narrative

Cannabis stocks surge as Trump consider reclassifying the drug

Cannabis stocks moved sharply higher on reports that President Donald Trump is considering rescheduling marijuana to a less restrictive drug category. The move would see marijuana reclassified from a Schedule I drug, along with heroin and cocaine, to Schedule III.

Cannabis stocks rally on Wall Street Journal report that Trump is weighing drug reclassification

Cannabis stocks rallied on a Wall Street Journal report that President Donald Trump is contemplating reclassifying weed as having a lower danger level. Such a move would be "a gamechanger" for the industry, one investing chief said.

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.

Best Canadian Cannabis Penny Stocks Under $5 to Watch Now

The U.S. cannabis industry remains a high-growth sector, valued at over $34 billion in 2024. Experts project it could reach $57 billion by 2030. Despite short-term volatility, marijuana penny stocks continue to attract attention from risk-tolerant investors. This week, traders are watching these low-priced stocks for potential breakouts. Many of these companies operate in emerging markets or hold licenses in high-demand states. Recently, a major Senate committee advanced a bill to expand cannabis banking access. This renewed optimism has sparked fresh momentum in the sector. As legalization efforts progress, smaller cannabis firms could benefit first from sudden volume spikes.

Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?

Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.

Cannabis Stocks Are at a Turning Point: Is Now the Time to Invest?

Currently, the cannabis industry is in another transitional period, presenting both challenges and potential opportunities for investors. After several years of volatility and downward trading, marijuana stocks are gaining renewed attention. Particularly as regulatory momentum builds and valuations reach attractive lows. While the sector has seen a sharp plunge over the past few years, mainly driven by market saturation, lagging federal reform in the U.S., and capital outflows.

Tilray Brands Reports In-Line Q4-2025 And FY2025 Results Amidst Weakening Sector

Tilray Brands posted sequential revenue growth but showed a decrease YoY. The company reported a high net loss due to non-cash impairments. Tilray Brands expects 2026 to be better than 2025, but uncertainty and risk remain.

Exploring Analyst Estimates for Tilray Brands (TLRY) Q4 Earnings, Beyond Revenue and EPS

Besides Wall Street's top-and-bottom-line estimates for Tilray Brands (TLRY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended May 2025.

Top Canadian Cannabis Picks for U.S. Market Expansion in 2025

As cannabis markets shift this week, Canadian cannabis stocks are once again gaining investor attention. At the same time, the U.S. industry continues to grow rapidly. In 2024, legal cannabis sales in the U.S. reached nearly $39 billion. Projections suggest that the number could climb past $44 billion in 2025. Growth is expected to continue at a strong pace through the decade. Despite this momentum, federal legalization remains stalled. However, several U.S. states are pushing forward with their own reform efforts. This steady progress at the state level continues to attract interest. Canadian companies with U.S. exposure stand to benefit …

Tilray Brands stock price is surging: time to buy or sell?

Tilray Brands stock price has triggered a short squeeze this month as it surged to a high of $0.6570, its highest point since April 1, and 90% from its lowest point this year. Its market capitalization has jumped to over $680 million.

3 Marijuana Stocks To Watch: Key Trends Driving Cannabis Industry Growth

Tilray Brands: Gambling A Little Money Now Could Generate Sizable Future Payoff

Tilray Brands is a high-risk, high-reward opportunity after a 99%+ decline over seven years, now trading at deep value levels with minimal bankruptcy risk. The company is nearing profitability, with projected positive cash flow in 2025-26, marking a significant turnaround from years of losses. Potential U.S. regulatory changes under President Trump could dramatically boost industry sentiment and Tilray's prospects.

Here Is A List Of 3 Canadian Marijuana Stocks To Watch 2025

The outlook for investing in marijuana stocks has changed for many. The sector is facing continuous dips and a serious lack of upward momentum. This has left many wondering what to do and how to take action to recoup their investment. It seems that, if not almost all, shareholders share the same fate. Shareholders will have to either cut their losses or continue to be patient till there is a change in the market.